Table 1.
Characteristic* | N (%) |
---|---|
Gender | |
Female | 32, 885 (68.4) |
Age group, years | |
30 | 9,200 (19.3) |
30 to < 40 | 21,073 (44.2) |
40 to < 50 | 12,163 (25.5) |
50+ | 5,258 (11) |
Marital status | |
Married/cohabiting | 20,448 (51) |
Widowed/divorced/separated | 64,896 (16.2) |
Single | 13,172 (32.8) |
District (residence) | |
Ilala | 14,272 (29.8) |
Kinondoni | 21,195 (44.3) |
Temeke | 12,429 (26) |
BMI group, kg/m2 | |
< 18.5 | 12,524 (26.8) |
18.5 to < 25 | 25,461 (54.5) |
25.0 to < 30 | 6,295 (13.5) |
30+ | 2,469 (5.2) |
WHO HIV disease stage | |
I | 6,479 (14.1) |
II | 9,125 (19.9) |
III | 21,715 (47.2) |
IV | 8,627 (18.8) |
CD4 count, cells/μL | |
< 50 | 8,070 (19) |
50 to < 200 | 16,018 (37.6) |
200+ | 18,464 (43.4) |
Medical history | |
No previous ART use | 41,324 (88.7) |
Previous ART use | 5,263 (11.3) |
TB history | 10,841 (24.5) |
Illnesses (OIs) | |
Oral candidiasis | 2,823 (6.4) |
Diarrhea | 2,627 (5.9) |
Kaposi's sarcoma | 278 (0.6) |
Biochemical tests | |
ALT > 120 U/L | 360 (1) |
Hepatitis B surface antigen | 650 (5.9) |
Creatinine > 1.2 mmol/L | 3,369 (15.1) |
Medications | |
On septrin prophylaxis | 10,987 (22.9) |
Taking a multivitamin | 8,289 (20.7) |
On TB treatment | 4,662 (9.7) |
Baseline regimen contains AZT† | 12,986 (27) |
Baseline regimen contains EFV† | 12,210 (25.2) |
Baseline ART regimen† | |
D4T, 3TC, NVP | 9,164 (36.7) |
D4T, 3TC, EFV | 2,842 (11.4) |
AZT, 3TC, NVP | 3,046 (12.2) |
AZT, 3TC, EFV | 9,940 (39.8) |
ALT = alanine aminotransferase; ART = antiretroviral treatment; AZT = zidovudine; BMI = body mass index; D4T = stavudine; EFV = efavirenz; HIV = human immunodeficiency virus; NVP = nevirapine; OIs = opportunistic infections; TB = tuberculosis; 3TC = lamivudine; WHO = World Health Organization.
Totals do not add up to 48,068 due to missing values.
Total is sub-population of those with at least two hemoglobin measures, who initiated ART at baseline.